Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Merck Sharp & Dohme LLC
Michael Boyer; Mehmet A N Şendur; Delvys Rodríguez-Abreu; Keunchil Park; Dae Ho Lee; Irfan Çiçin; Perran Fulden Yumuk; Francisco J Orlandi; Ticiana A Leal; Olivier Molinier; Nopadol Soparattanapaisarn; Adrian Langleben; Raffaele Califano; Balazs Medgyasszay; Te-Chun Hsia; Gregory A Otterson; Lu Xu; Bilal Piperdi; Ayman Samkari; Martin Reck; KEYNOTE-598 Investigators